S3-E49.1 - NICE on FibroScan for Primary Care
Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) ...
15 Okt 202214min
S3-E49 - NICE and VCTE Use in Community Settings
Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) ...
13 Okt 202259min
S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies
Send us Fan Mail In Season 3, Episode 6, Roger Green assembles audio clips from Surfing the NASH Tsunami’s coverage of NASH-TAG 2022 to reveal an evolving view of the role combination therapies will p...
9 Okt 202219min
S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept
Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. This conversation explores the single unsuccessful tr...
9 Okt 202210min
S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study
Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, the panel continues exploring o...
9 Okt 202210min
S3-E48.3 - More Positive Phase 2B Results from Poxel
Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Stephen Harrison continues his ...
8 Okt 202213min
S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial
Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen ...
8 Okt 202214min
S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide
Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen ...
8 Okt 202212min
